Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Atorvastatin 80mg granted 13% price boost, CPE announces

The Department of Health and Social Care (DH) has granted pharmacies a 13% increase on the previously imposed tariff for 80mg atorvastatin dispensed in July.

The price concession for atorvastatin 80mg has been increased to £3.91 for prescriptions dispensed in July, Community Pharmacy England (CPE) announced yesterday (August 9).

CPE said that the improved price is now enough to cover the costs of “the majority” of community pharmacies that report prices to it.

Read more: ‘Frustrating’: DH 'imposed' atorvastatin 20mg and 80mg concessions, says CP

The DH had "imposed" a price of £3.45 in its final price concession list for July, released last week (July 31).

It also imposed a concession price of £3.38 for atorvastatin 20mg.

CPE yesterday said that it had received an “exceptionally high” number of reports from community pharmacies in July about their inability to buy atorvastatin 80mg at the tariff price.

Read more: ‘Four-figure loss’: Pharmacy contractors rage at atorvastatin crisis

The negotiator added that it made “further representations” to the government, indicating that pharmacies continued to report “ongoing concerns” that they could not buy atorvastatin 80mg at the imposed concession price.

Meanwhile, CPE said that it had “frustratingly” been unable to change the concession prices for two other items.

It added that it would be “pushing back” and “challenging” the “accuracy and quality” of the data that the government uses to set concessions. 




It comes as C+D last week released the results of an exclusive poll of pharmacy contractors, revealing that 47% were facing losses of over £1,000 from dispensing atorvastatin in July.

Just 22% of respondents said that they would not incur a loss from dispensing the medicine, which is in short supply.

Atorvastatin was the most dispensed drug in England during 2022/2023, with 58.7 million items dispensed according to the NHS Business Services Authority’s (NHSBSA) prescription cost analysis for that year.

Related Content


Pharmacy Manager

Apply Now
Latest News & Analysis
See All



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts